Transcript - Actos - Diabetes Drug Linked to Bladder Cancer
Diabetes drug Actos may raise the risk of bladder cancer. Actos manufactured by Takeda (the largest drug maker in Japan) and marketed by US drug maker Eli Lilly, is one of the most popular diabetes drugs in the world. The FDA has issued a formal warning stating Actos may increase the risk of bladder cancer when used for more than a year.
In a study involving more than 193,000 patients, those who took Actos for longer then 12 months were associated with a 40% increase for bladder cancer. In 2010, more than 2 million patients were taking these drugs. The American Cancer Society estimates approximately 75,000 new cases of bladder cancer and 16,000 deaths in 2014.
There are over 5,500 Actos personal injury and wrongful death lawsuits pending in the United States. In a recent Actos trial, a jury awarded over $9 billion in damages to a single plaintiff. It was alleged that Takeda officials purposely destroyed potentially damaging documents related to Actos.
In France, the agency for safety of health products recalled Actos from the market. Regulators in Germany recommended that physicians not prescribe it. However, in the United States Actos is still available.
Our goal at Moll Law Group is to inform consumers of potentially dangerous products and provide assistance with the filing of claims. If you have a case and would like a prompt and confidential evaluation, please fill out our free consultation form. For free consumer safety information and case updates, visit us at legalnewsnetwork.com